{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T04:13:14Z","timestamp":1769746394395,"version":"3.49.0"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,6,4]],"date-time":"2020-06-04T00:00:00Z","timestamp":1591228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,6,4]],"date-time":"2020-06-04T00:00:00Z","timestamp":1591228800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Heart Fail Rev"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1007\/s10741-020-09984-2","type":"journal-article","created":{"date-parts":[[2020,6,4]],"date-time":"2020-06-04T07:02:33Z","timestamp":1591254153000},"page":"119-134","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Hormonal prostate cancer therapies and cardiovascular disease: a systematic review"],"prefix":"10.1007","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3717-0655","authenticated-orcid":false,"given":"Vittore","family":"Cereda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pina T.","family":"Falbo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gaia","family":"Manna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Iannace","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonello","family":"Menghi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michela","family":"Corona","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diana","family":"Semenova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leonardo","family":"Cal\u00f2","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Carnevale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giacomo","family":"Frati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gaetano","family":"Lanzetta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,6,4]]},"reference":[{"issue":"6","key":"9984_CR1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68(6):394\u2013424","journal-title":"CA Cancer J Clin"},{"key":"9984_CR2","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1200\/JCO.2006.10.1949","volume":"25","author":"DA Loblaw","year":"2007","unstructured":"Loblaw DA, Virgo KS, Nam R, Somerfield MR, Ben-Josef E, Mendelson DS, Middleton R, Sharp SA, Smith TJ, Talcott J, Taplin M, Vogelzang NJ, Wade JL 3rd, Bennett CL, Scher HI, American Society of Clinical Oncology (2007) Initial hormonal management of androgen sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol 25:1596\u20131605","journal-title":"J Clin Oncol"},{"key":"9984_CR3","doi-asserted-by":"publisher","unstructured":"Sargos P, Mottet N, Bellera C, Richaud P (2019) Long-term androgen deprivation, with or without radiotherapy, un locally-advanced prostate cancer: updated results from a phase III randomized trial. BJU Int. https:\/\/doi.org\/10.1111\/bju.i4768","DOI":"10.1111\/bju.i4768"},{"issue":"3","key":"9984_CR4","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/j.juro.2011.04.083","volume":"186","author":"ED Crawford","year":"2011","unstructured":"Crawford ED, Tombal B, Miller K, Boccon-Gibod L, Schr\u00f6der F, Shore N, Moul JW, Jensen JK, Olesen TK, Persson BE (2011) A phase III extension trial with 1-arm crossover from leuprolide to degarelix: comparison of gonadotropin-releasing hormone agonist and antagonist effect on prostate cancer. J Urol 186(3):889\u2013897","journal-title":"J Urol"},{"issue":"1","key":"9984_CR5","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.eururo.2018.07.027","volume":"75","author":"L Tosco","year":"2019","unstructured":"Tosco L, Briganti A, D\u2019amico AV et al (2019) Systematic review of systemic therapies and therapeutic combinations with local treatments for high-risk localized prostate cancer. Eur Urol 75(1):44\u201360","journal-title":"Eur Urol"},{"key":"9984_CR6","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1200\/JCO.2015.64.8055","volume":"34","author":"M Bolla","year":"2016","unstructured":"Bolla M, Maingon P, Carrie C, Villa S, Kitsios P, Poortmans PMP, Sundar S, van der Steen-Banasik EM, Armstrong J, Bosset JF, Herrera FG, Pieters B, Slot A, Bahl A, Ben-Yosef R, Boehmer D, Scrase C, Renard L, Shash E, Coens C, van den Bergh ACM, Collette L (2016) Short androgen suppression and radiation dose escalation for intermediate- and high-risk localized prostate cancer: results of EORTC trial 22991. J Clin Oncol 34:1748\u20131756","journal-title":"J Clin Oncol"},{"issue":"5","key":"9984_CR7","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/S0022-5347(05)67032-2","volume":"164","author":"P Iversen","year":"2000","unstructured":"Iversen P, Tyrrel CJ, Kaisary AV et al (2000) Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of follow up. J Urol 164(5):1579\u20131582","journal-title":"J Urol"},{"issue":"15","key":"9984_CR8","doi-asserted-by":"crossref","first-page":"3437","DOI":"10.1002\/cncr.24395","volume":"115","author":"H Azaka","year":"2009","unstructured":"Azaka H, Hinotsu S, Usami M et al (2009) Combined androgen blockade with bicalutamide for advanced prostate cancer: long-term follow-up for a phase 3, double-blind, randomized study for survival. Cancer 115(15):3437\u20133445","journal-title":"Cancer"},{"issue":"2","key":"9984_CR9","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/cncr.10647","volume":"95","author":"DJ Samson","year":"2002","unstructured":"Samson DJ, Seidenfeld J, Schmitt B, Hasselblad V, Albertsen PC, Bennett CL, Wilt TJ, Aronson N (2002) Systematic review and meta-analyses of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma. Cancer 95(2):361\u2013376","journal-title":"Cancer"},{"key":"9984_CR10","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.eururo.2012.12.029","volume":"64","author":"A Omlin","year":"2013","unstructured":"Omlin A, Pezaro C, Mukherji D, Mulick Cassidy A, Sandhu S, Bianchini D, Olmos D, Ferraldeschi R, Maier G, Thompson E, Parker C, Attard G, de Bono J (2013) Improved survival in a cohort of trial participants with metastatic castration-resistant prostate cancer demonstrates the need for updated prognostic nomograms. Eur Urol 64:300\u2013306","journal-title":"Eur Urol"},{"issue":"1","key":"9984_CR11","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.clgc.2016.08.018","volume":"15","author":"DM Moreira","year":"2017","unstructured":"Moreira DM, Howard LE, Sourbeer KN et al (2017) Predicting time from metastasis to overall survival in castration-resistant prostate cancer: results from SEARCH. Clin Genitourin Cancer 15(1):60\u201366.e2","journal-title":"Clin Genitourin Cancer"},{"issue":"2","key":"9984_CR12","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMoa1209096","volume":"368","author":"CJ Ryan","year":"2013","unstructured":"Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, Fizazi K, Mainwaring P, Piulats JM, Ng S, Carles J, Mulders PF, Basch E, Small EJ, Saad F, Schrijvers D, van Poppel H, Mukherjee SD, Suttmann H, Gerritsen WR, Flaig TW, George DJ, Yu EY, Efstathiou E, Pantuck A, Winquist E, Higano CS, Taplin ME, Park Y, Kheoh T, Griffin T, Scher HI, Rathkopf DE, COU-AA-302 Investigators (2013) Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 368(2):138\u2013148","journal-title":"N Engl J Med"},{"issue":"2","key":"9984_CR13","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/S1470-2045(14)71205-7","volume":"16","author":"CJ Ryan","year":"2015","unstructured":"Ryan CJ, Smith MR, Fizazi K, Saad F, Mulders PF, Sternberg CN, Miller K, Logothetis CJ, Shore ND, Small EJ, Carles J, Flaig TW, Taplin ME, Higano CS, de Souza P, de Bono JS, Griffin TW, de Porre P, Yu MK, Park YC, Li J, Kheoh T, Naini V, Molina A, Rathkopf DE, COU-AA-302 Investigators (2015) Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 16(2):152\u2013160","journal-title":"Lancet Oncol"},{"issue":"21","key":"9984_CR14","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","volume":"364","author":"JS De Bono","year":"2011","unstructured":"De Bono JS, Logothetis CJ, Molina A et al (2011) Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 364(21):1995\u20132005","journal-title":"N Engl J Med"},{"issue":"10","key":"9984_CR15","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S1470-2045(12)70379-0","volume":"13","author":"K Fizazi","year":"2012","unstructured":"Fizazi K, Scher HI, Molina A, Logothetis CJ, Chi KN, Jones RJ, Staffurth JN, North S, Vogelzang NJ, Saad F, Mainwaring P, Harland S, Goodman OB Jr, Sternberg CN, Li JH, Kheoh T, Haqq CM, de Bono JS, COU-AA-301 Investigators (2012) Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 13(10):983\u2013992","journal-title":"Lancet Oncol"},{"issue":"4","key":"9984_CR16","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1056\/NEJMoa1704174","volume":"377","author":"K Fizazi","year":"2017","unstructured":"Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, \u00d6zg\u00fcro\u011flu M, Ye D, Feyerabend S, Protheroe A, de Porre P, Kheoh T, Park YC, Todd MB, Chi KN (2017) Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med 377(4):352\u2013360","journal-title":"N Engl J Med"},{"issue":"4","key":"9984_CR17","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1702900","volume":"377","author":"ND James","year":"2017","unstructured":"James ND, de Bono JS, Spears MR, Clarke NW, Mason MD, Dearnaley DP, Ritchie AWS, Amos CL, Gilson C, Jones RJ, Matheson D, Millman R, Attard G, Chowdhury S, Cross WR, Gillessen S, Parker CC, Russell JM, Berthold DR, Brawley C, Adab F, Aung S, Birtle AJ, Bowen J, Brock S, Chakraborti P, Ferguson C, Gale J, Gray E, Hingorani M, Hoskin PJ, Lester JF, Malik ZI, McKinna F, McPhail N, Money-Kyrle J, O'Sullivan J, Parikh O, Protheroe A, Robinson A, Srihari NN, Thomas C, Wagstaff J, Wylie J, Zarkar A, Parmar MKB, Sydes MR, STAMPEDE Investigators (2017) Abiraterone for prostate cancer not previously treated with hormone therapy. N Engl J Med 377(4):338\u2013351","journal-title":"N Engl J Med"},{"issue":"13","key":"9984_CR18","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","volume":"367","author":"HI Scher","year":"2012","unstructured":"Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, de Wit R, Mulders P, Chi KN, Shore ND, Armstrong AJ, Flaig TW, Fl\u00e9chon A, Mainwaring P, Fleming M, Hainsworth JD, Hirmand M, Selby B, Seely L, de Bono JS (2012) Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 367(13):1187\u20131197","journal-title":"N Engl J Med"},{"issue":"5","key":"9984_CR19","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1056\/NEJMoa1405095","volume":"371","author":"TM Beer","year":"2014","unstructured":"Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, Iversen P, Bhattacharya S, Carles J, Chowdhury S, Davis ID, de Bono JS, Evans CP, Fizazi K, Joshua AM, Kim CS, Kimura G, Mainwaring P, Mansbach H, Miller K, Noonberg SB, Perabo F, Phung D, Saad F, Scher HI, Taplin ME, Venner PM, Tombal B, PREVAIL Investigators (2014) Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 371(5):424\u2013433","journal-title":"N Engl J Med"},{"issue":"2","key":"9984_CR20","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.eururo.2016.07.032","volume":"71","author":"TM Beer","year":"2017","unstructured":"Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, Iversen P, Evans CP, Kim CS, Kimura G, Miller K, Saad F, Bjartell AS, Borre M, Mulders P, Tammela TL, Parli T, Sari S, van Os S, Theeuwes A, Tombal B (2017) Enzalutamide in men with chemotherapy-naive metastatic castration-resistant prostate cancer: extended analysis of the phase 3 PREVAIL study. Eur Urol 71(2):151\u2013154","journal-title":"Eur Urol"},{"issue":"26","key":"9984_CR21","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1056\/NEJMoa1800536","volume":"378","author":"M Hussain","year":"2018","unstructured":"Hussain M, Fizazi K, Saad F, Rathenborg P, Shore N, Ferreira U, Ivashchenko P, Demirhan E, Modelska K, Phung D, Krivoshik A, Sternberg CN (2018) Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer. N Engl J Med 378(26):2465\u20132474","journal-title":"N Engl J Med"},{"key":"9984_CR22","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1056\/NEJMoa1903835","volume":"381","author":"ID Davis","year":"2019","unstructured":"Davis ID, Martin AJ, Stockler MR, Begbie S, Chi KN, Chowdhury S, Coskinas X, Frydenberg M, Hague WE, Horvath LG, Joshua AM, Lawrence NJ, Marx G, McCaffrey J, McDermott R, McJannett M, North SA, Parnis F, Parulekar W, Pook DW, Reaume MN, Sandhu SK, Tan A, Tan TH, Thomson A, Tu E, Vera-Badillo F, Williams SG, Yip S, Zhang AY, Zielinski RR, Sweeney CJ (2019) Enzalutamide with standard first-line therapy in metastatic prostate cancer. N Engl J Med 381:121\u2013131. https:\/\/doi.org\/10.1056\/NEJMoa1903835","journal-title":"N Engl J Med"},{"key":"9984_CR23","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1161\/CIRCULATIONAHA.115.012519","volume":"133","author":"N Bhatia","year":"2016","unstructured":"Bhatia N, Santos M, Jones LW, Beckman JA, Penson DF, Morgans AK, Moslehi J (2016) Cardiovascular effects of androgen deprivation therapy for the treatment of prostate cancer: ABCDE steps to reduce cardiovascular disease in patients with prostate cancer. Circulation 133:537\u2013541","journal-title":"Circulation"},{"issue":"10","key":"9984_CR24","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1200\/JOP.18.00178","volume":"14","author":"D Gupta","year":"2018","unstructured":"Gupta D, Lee Chuy K, Yang JC, Bates M, Lombardo M, Steingart RM (2018) Cardiovascular and metabolic effects of androgen-deprivation therapy for prostate cancer. J Oncol Pract 14(10):580\u2013587","journal-title":"J Oncol Pract"},{"key":"9984_CR25","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1200\/JCO.2014.59.1792","volume":"33","author":"S O\u2019Farrell","year":"2015","unstructured":"O\u2019Farrell S, Garmo H, Holmberg L et al (2015) Risk and timing of cardiovascular disease after androgen-deprivation therapy in men with prostate cancer. J Clin Oncol 33:1243\u20131251","journal-title":"J Clin Oncol"},{"key":"9984_CR26","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1093\/cvr\/cvz020","volume":"115","author":"M Barber","year":"2019","unstructured":"Barber M, Nguyen LS, Wassermann J, Spano JP, Funck-Brentano C, Salem JE (2019) Cardiac arrhythmia considerations of hormone cancer therapies. Cardiovasc Res 115:878\u2013894","journal-title":"Cardiovasc Res"},{"issue":"4","key":"9984_CR27","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1038\/nrurol.2016.273","volume":"14","author":"A Veccia","year":"2017","unstructured":"Veccia A, Maines F, Kinspergher S, Galligioni E, Caffo O (2017) Cardiovascular toxicities of systemic treatments of prostate cancer. Nat Rev Urol 14(4):230\u2013243","journal-title":"Nat Rev Urol"},{"issue":"6","key":"9984_CR28","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1161\/CIRCULATIONAHA.109.192695","volume":"121","author":"GN Levine","year":"2010","unstructured":"Levine GN, D\u2019Amico AV, Berger P et al (2010) Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology. Circulation 121(6):833\u2013840","journal-title":"Circulation"},{"issue":"26","key":"9984_CR29","doi-asserted-by":"crossref","first-page":"3271","DOI":"10.1200\/JCO.2011.38.8850","volume":"30","author":"MR Smith","year":"2012","unstructured":"Smith MR, Saad F, Egerdie B, Sieber PR, Tammela TLJ, Ke C, Leder BZ, Goessl C (2012) Sarcopenia during androgen-deprivation therapy for prostate cancer. J Clin Oncol 30(26):3271\u20133276","journal-title":"J Clin Oncol"},{"issue":"27","key":"9984_CR30","doi-asserted-by":"crossref","first-page":"4448","DOI":"10.1200\/JCO.2006.06.2497","volume":"24","author":"NL Keating","year":"2006","unstructured":"Keating NL, O\u2019Malley AJ, Smith MR (2006) Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 24(27):4448\u20134456","journal-title":"J Clin Oncol"},{"issue":"9\u201310","key":"9984_CR31","doi-asserted-by":"crossref","first-page":"E300","DOI":"10.5489\/cuaj.3655","volume":"10","author":"MM Rezaei","year":"2016","unstructured":"Rezaei MM, Rezaei MM, Ghoreifi A, Kerigh BF (2016) Metabolic syndrome in patients with prostate cancer undergoing intermittent androgen-deprivation therapy. Can Urol Assoc J 10(9\u201310):E300\u2013E305","journal-title":"Can Urol Assoc J"},{"issue":"5","key":"9984_CR32","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1210\/js.2018-00039","volume":"2","author":"T Gagliano-Juc\u00e0","year":"2018","unstructured":"Gagliano-Juc\u00e0 T, Travison TG, Kantoff PW et al (2018) Androgen deprivation therapy is associated with prolongation of QTc interval in men with prostate cancer. J Endocr Soc 2(5):485\u2013496","journal-title":"J Endocr Soc"},{"issue":"6","key":"9984_CR33","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1016\/j.juro.2010.08.012","volume":"184","author":"MR Smith","year":"2010","unstructured":"Smith MR, Klotz L, Persson BE, Olesen TK, Wilde AAM (2010) Cardiovascular safety of degarelix: results from a 12-month, comparative, randomized, open label, parallel group phase III trial in patients with prostate cancer. J Urol 184(6):2313\u20132319","journal-title":"J Urol"},{"key":"9984_CR34","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1161\/CIRCULATIONAHA.118.034282","volume":"138","author":"JE Salem","year":"2018","unstructured":"Salem JE, Waintraub X, Courtillot C, Shaffer CM, Gandjbakhch E, Maupain C, Moslehi JJ, Badilini F, Haroche J, Gougis P, Fressart V, Glazer AM, Hidden-Lucet F, Touraine P, Lebrun-Vignes B, Roden DM, Bachelot A, Funck-Brentano C (2018) Hypogonadism as a reversible cause of torsades de pointes in men. Circulation 138:110\u2013113","journal-title":"Circulation"},{"key":"9984_CR35","first-page":"356","volume":"17","author":"E Lubart","year":"2015","unstructured":"Lubart E, Yarovoy A, Gal G, Krakover R, Leibovitz A (2015) QT interval lenght in elderly prostatic cancer patients on anti-testosterone treatment. Isr Med Assoc J 17:356\u2013359","journal-title":"Isr Med Assoc J"},{"key":"9984_CR36","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1177\/1756287215617872","volume":"8","author":"P Zareba","year":"2016","unstructured":"Zareba P, Duivenvoorden W, Leong DP, Pinthus JH (2016) Androgen deprivation therapy and cardiovascular disease: what is the linking mechanism? Ther Adv Urol 8:118\u2013129","journal-title":"Ther Adv Urol"},{"key":"9984_CR37","doi-asserted-by":"crossref","first-page":"e107516","DOI":"10.1371\/journal.pone.0107516","volume":"9","author":"J Zhao","year":"2014","unstructured":"Zhao J, Zhu S, Sun L, Meng F, Zhao L, Zhao Y, Tian H, Li P, Niu Y (2014) Androgen deprivation therapy for prostate cancer is associated with cardiovascular morbidity and mortality: a meta-analysis of population-based observational studies. PLoS One 9:e107516","journal-title":"PLoS One"},{"key":"9984_CR38","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1186\/s12885-016-2221-5","volume":"16","author":"F Meng","year":"2016","unstructured":"Meng F, Zhu S, Zhao J, Vados L, Wang L, Zhao Y, Zhao D, Niu Y (2016) Stroke related to androgen deprivation therapy for prostate cancer: a meta-analysis and systematic review. BMC Cancer 16:180","journal-title":"BMC Cancer"},{"issue":"3","key":"9984_CR39","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.eururo.2014.11.039","volume":"68","author":"C Bosco","year":"2015","unstructured":"Bosco C, Bosnyak Z, Malmberg A, Adolfsson J, Keating NL, van Hemelrijck M (2015) Quantifying observational evidence for risk of fatal and nonfatal cardiovascular disease following androgen deprivation therapy for prostate cancer: a meta-analysis. Eur Urol 68(3):386\u2013396","journal-title":"Eur Urol"},{"issue":"3","key":"9984_CR40","doi-asserted-by":"crossref","first-page":"e123","DOI":"10.1016\/j.clgc.2014.12.003","volume":"13","author":"G Gandaglia","year":"2015","unstructured":"Gandaglia G, Sun M, Popa I, Schiffmann J, Trudeau V, Shariat SF, Trinh QD, Graefen M, Widmer H, Saad F, Briganti A, Montorsi F, Karakiewicz PI (2015) Cardiovascular mortality in patients with metastatic prostate cancer exposed to androgen deprivation therapy: a population-based study. Clin Genitourin Cancer 13(3):e123\u2013e130","journal-title":"Clin Genitourin Cancer"},{"issue":"3","key":"9984_CR41","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1111\/bju.12905","volume":"116","author":"DR Ziehr","year":"2015","unstructured":"Ziehr DR, Chen MH, Zhang D, Braccioforte MH, Moran BJ, Mahal BA, Hyatt AS, Basaria SS, Beard CJ, Beckman JA, Choueiri TK, D\u2019Amico AV, Hoffman KE, Hu JC, Martin NE, Sweeney CJ, Trinh QD, Nguyen PL (2015) Association of androgen-deprivation therapy with excess cardiac-specific mortality in men with prostate cancer. BJU Int 116(3):358\u2013365","journal-title":"BJU Int"},{"issue":"8","key":"9984_CR42","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.acuro.2015.01.004","volume":"39","author":"JI Monz\u00f2-Gardiner","year":"2015","unstructured":"Monz\u00f2-Gardiner JI, Herranz-Amo F (2015) Cardiovascular mortality in patients with prostate cancer exposed to androgen deprivation therapy. Actas Urol Esp 39(8):518\u2013522","journal-title":"Actas Urol Esp"},{"key":"9984_CR43","doi-asserted-by":"publisher","unstructured":"Lester-Coll NH, Johnson S, Magnuson WJ et al (2016) Weighing risk of cardiovascular mortality against potential benefit of hormonal therapy in intermediate-risk prostate cancer. J Natl Cancer Inst 109(6). https:\/\/doi.org\/10.1093\/jnci\/djw281","DOI":"10.1093\/jnci\/djw281"},{"issue":"8","key":"9984_CR44","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1038\/bjc.2017.280","volume":"117","author":"R Haque","year":"2017","unstructured":"Haque R, Ulcickas Yood M, Xu X et al (2017) Cardiovascular disease risk and androgen deprivation therapy in patients with localised prostate cancer: a prospective cohort study. Br J Cancer 117(8):1233\u20131240","journal-title":"Br J Cancer"},{"issue":"2","key":"9984_CR45","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.ijrobp.2016.06.2445","volume":"96","author":"A Zapatero","year":"2016","unstructured":"Zapatero A, Guerrero A, Maldonado X, \u00c1lvarez A, Gonz\u00e1lez-San Segundo C, Cabeza Rodriguez MA, Mac\u00edas V, Pedro Olive A, Casas F, Boladeras A, Mart\u00edn de Vidales C, V\u00e1zquez de la Torre ML, Calvo FA (2016) Late radiation and cardiovascular adverse effects after androgen deprivation and high-dose radiation therapy in prostate cancer: results from the DART 01\/05 randomized phase 3 trial. Int J Radiat Oncol Biol Phys 96(2):341\u2013348","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"21","key":"9984_CR46","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1001\/jama.2011.1745","volume":"306","author":"PL Nguyen","year":"2011","unstructured":"Nguyen PL, Je Y, Schutz FAB, Hoffman KE, Hu JC, Parekh A, Beckman JA, Choueiri TK (2011) Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials. JAMA 306(21):2359\u20132366","journal-title":"JAMA"},{"issue":"1","key":"9984_CR47","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1159\/000334999","volume":"82","author":"C Wilcox","year":"2012","unstructured":"Wilcox C, Kautto A, Steigler et al (2012) Androgen deprivation therapy for prostate cancer does not increase cardiovascular mortality in the long term. Oncology 82(1):56\u201358","journal-title":"Oncology"},{"issue":"14","key":"9984_CR48","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1056\/NEJMoa1212299","volume":"368","author":"M Hussain","year":"2013","unstructured":"Hussain M, Tangen CM, Berry DL, Higano CS, Crawford ED, Liu G, Wilding G, Prescott S, Kanaga Sundaram S, Small EJ, Dawson NA, Donnelly BJ, Venner PM, Vaishampayan UN, Schellhammer PF, Quinn DI, Raghavan D, Ely B, Moinpour CM, Vogelzang NJ, Thompson IM Jr (2013) Intermittent versus continuous androgen deprivation in prostate cancer. N Engl J Med 368(14):1314\u20131325","journal-title":"N Engl J Med"},{"issue":"27","key":"9984_CR49","doi-asserted-by":"crossref","first-page":"e3845","DOI":"10.1097\/MD.0000000000003845","volume":"95","author":"A Sciarra","year":"2016","unstructured":"Sciarra A, Fasulo A, Ciardi A, Petrangeli E, Gentilucci A, Maggi M, Innocenzi M, Pierella F, Gentile V, Salciccia S, Cattarino S (2016) A meta-analysis and systematic review of randomized controlled trials with degarelix versus gonadotropin-releasing hormone agonists for advanced prostate cancer. Medicine (Baltimore) 95(27):e3845","journal-title":"Medicine (Baltimore)"},{"issue":"3","key":"9984_CR50","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.eururo.2013.10.032","volume":"65","author":"PC Albertsen","year":"2014","unstructured":"Albertsen PC, Klotz L, Tombal B, Grady J, Olesen TK, Nilsson J (2014) Cardiovascular morbidity associated with gonadotropin releasing hormone agonists and an antagonist. Eur Urol 65(3):565\u2013573","journal-title":"Eur Urol"},{"key":"9984_CR51","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ejca.2017.03.002","volume":"77","author":"LM Scailteux","year":"2017","unstructured":"Scailteux LM, Vincendeau S, Balusson F, Leclercq C, Happe A, le Nautout B, Polard E, Nowak E, Oger E (2017) Androgen deprivation therapy and cardiovascular risk: no meaningful difference between GnRH antagonist and agonists - a nationwide population-based cohort study based on 2010-2013 French health insurance data. Eur J Cancer 77:99\u2013108","journal-title":"Eur J Cancer"},{"issue":"5","key":"9984_CR52","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.urolonc.2017.01.025","volume":"35","author":"ED Crawford","year":"2017","unstructured":"Crawford ED, Schally AV, Pinthus JH, Block NL, Rick FG, Garnick MB, Eckel RH, Keane TE, Shore ND, Dahdal DN, Beveridge TJR, Marshall DC (2017) The potential role of follicle-stimulating hormone in the cardiovascular, metabolic, skeletal and cognitive effects associated with androgen deprivation therapy. Urol Oncol 35(5):183\u2013191","journal-title":"Urol Oncol"},{"issue":"suppl","key":"9984_CR53","doi-asserted-by":"crossref","first-page":"TPS395","DOI":"10.1200\/JCO.2018.36.6_suppl.TPS395","volume":"36","author":"SF Slovin","year":"2018","unstructured":"Slovin SF, Melloni C, Mansor-Lefebvre S et al (2018) A multicenter, randomized, controlled trial comparing the occurrence of major adverse cardiovascular events (MACEs) in patients (pts) with prostate cancer (pc) and cardiovascular disease (CVD) receiving degarelix (GnRH receptor antagonist) or leuprolide (GnRH receptor agonist). J Clin Oncol 36(suppl):TPS395","journal-title":"J Clin Oncol"},{"key":"9984_CR54","doi-asserted-by":"crossref","first-page":"14698","DOI":"10.1038\/s41598-017-14413-w","volume":"7","author":"N Melong","year":"2017","unstructured":"Melong N, Steele S, MacDonald M, Holly A, Collins CC, Zoubeidi A, Berman JN, Dellaire G (2017) Enzalutamide inhibits testosterone-induced growth of human prostate cancer xenografts in zebrafish and can induce bradycardia. Sci Rep 7:14698","journal-title":"Sci Rep"},{"key":"9984_CR55","first-page":"27","volume":"13","author":"A Pozniak","year":"2008","unstructured":"Pozniak A (2008) New drugs: enzalutamide. J HIV Ther 13:27\u201333","journal-title":"J HIV Ther"},{"issue":"2","key":"9984_CR56","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S1470-2045(15)00518-5","volume":"17","author":"ND Shore","year":"2016","unstructured":"Shore ND, Chowdhury S, Villers A, Klotz L, Siemens DR, Phung D, van Os S, Hasabou N, Wang F, Bhattacharya S, Heidenreich A (2016) Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomised, double-blind, phase 2 study. Lancet Oncol 17(2):153\u2013163","journal-title":"Lancet Oncol"},{"issue":"8","key":"9984_CR57","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1002\/pros.22965","volume":"75","author":"AM Joshua","year":"2015","unstructured":"Joshua AM, Shore ND, Saad F, Chi KN, Olsson CA, Emmenegger U, Scholz M, Berry W, Mukherjee SD, Winquist E, Haas NB, Foley MA, Dmuchowski C, Perabo F, Hirmand M, Hasabou N, Rathkopf D, for The Enzalutamide Expanded Access Study Investigators (2015) Safety of enzalutamide in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel: expanded access in North America. Prostate 75(8):836\u2013844","journal-title":"Prostate"},{"issue":"3","key":"9984_CR58","doi-asserted-by":"crossref","first-page":"e645","DOI":"10.1016\/j.clgc.2017.12.007","volume":"16","author":"R Iacovelli","year":"2018","unstructured":"Iacovelli R, Ciccarese C, Bria E, Romano M, Fantinel E, Bimbatti D, Muraglia A, Porcaro AB, Siracusano S, Brunelli M, Mazzarotto R, Artibani W, Tortora G (2018) The cardiovascular toxicity of abiraterone and enzalutamide in prostate cancer. Clin Genitourin Cancer 16(3):e645\u2013e653","journal-title":"Clin Genitourin Cancer"},{"issue":"8","key":"9984_CR59","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1001\/jamaoncol.2019.1011","volume":"5","author":"G Attard","year":"2019","unstructured":"Attard G, Mersebburger AS, Wiebke A et al (2019) Assessment of the safety of glucocorticoid regimens in combination with abiraterone acetate for metastatic castration-resistant prostate cancer: a randomized, open-label phase 2 study. JAMA Oncol 5(8):1159\u20131167","journal-title":"JAMA Oncol"},{"issue":"2","key":"9984_CR60","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s00280-012-1916-9","volume":"70","author":"AW Tolcher","year":"2012","unstructured":"Tolcher AW, Chi KN, Shore ND, Pili R, Molina A, Acharya M, Kheoh T, Jiao JJ, Gonzalez M, Trinh A, Pankras C, Tran N (2012) Effect of abiraterone acetate plus prednisone on the QT interval in patients with metastatic castration-resistant prostate cancer. Cancer Cemother Pharmacol 70(2):305\u2013313","journal-title":"Cancer Cemother Pharmacol"},{"issue":"11","key":"9984_CR61","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/S1470-2045(14)70417-6","volume":"15","author":"CN Sternberg","year":"2014","unstructured":"Sternberg CN, Castellano D, Daugaard G, G\u00e9czi L, Hotte SJ, Mainwaring PN, Saad F, Souza C, Tay MH, Garrido JM, Galli L, Londhe A, de Porre P, Goon B, Lee E, McGowan T, Naini V, Todd MB, Molina A, George DJ, Abiraterone Global EAP Investigators (2014) Abiraterone acetate for patients with metastatic castration-resistant prostate cancer progressing after chemotherapy: final analysis of a multicentre, open-label, early-access protocol trial. Lancet Oncol 15(11):1263\u20131268","journal-title":"Lancet Oncol"},{"issue":"5","key":"9984_CR62","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/j.eururo.2014.02.056","volume":"66","author":"DE Rathkopf","year":"2014","unstructured":"Rathkopf DE, Smith MR, de Bono JS, Logothetis CJ, Shore ND, de Souza P, Fizazi K, Mulders PFA, Mainwaring P, Hainsworth JD, Beer TM, North S, Fradet Y, van Poppel H, Carles J, Flaig TW, Efstathiou E, Yu EY, Higano CS, Taplin ME, Griffin TW, Todd MB, Yu MK, Park YC, Kheoh T, Small EJ, Scher HI, Molina A, Ryan CJ, Saad F (2014) Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302). Eur Urol 66(5):815\u2013825","journal-title":"Eur Urol"},{"key":"9984_CR63","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.ejca.2017.07.003","volume":"84","author":"LHM Rydzewska","year":"2017","unstructured":"Rydzewska LHM, Burdett S, Vale CL, Clarke NW, Fizazi K, Kheoh T, Mason MD, Miladinovic B, James ND, Parmar MKB, Spears MR, Sweeney CJ, Sydes MR, Tran N, Tierney JF, STOPCaP Abiraterone Collaborators (2017) Adding abiraterone to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: a systematic review and meta-analysis. Eur J Cancer 84:88\u2013101","journal-title":"Eur J Cancer"},{"issue":"6","key":"9984_CR64","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.tranon.2016.08.001","volume":"9","author":"S Campora","year":"2016","unstructured":"Campora S, Campazzi E, Zanardi S, Puntoni M, Piccininno M, Piccardo A, Shoushtari Zadeh Naseri M, Defferrari C, Provinciali N, Petrera M, Marra D, Biscaldi E, Antonucci GC, Ricci D, Clavarezza M, Gennari A, Gozza A, D'Amico M, Mori M, DeCensi A (2016) Association of biomarkers with serious cardiac adverse events during abiraterone acetate treatment in castration resistant prostate cancer. Transl Oncol 9(6):600\u2013605","journal-title":"Transl Oncol"},{"issue":"5","key":"9984_CR65","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1097\/COC.0b013e3182a790ce","volume":"38","author":"G Procopio","year":"2015","unstructured":"Procopio G, Grassi P, Testa I, Verzoni E, Torri V, Salvioni R, Valdagni R, de Braud F (2015) Safety of abiraterone acetate in castration-resistant prostate cancer patients with concomitant cardiovascular risk factors. Am J Clin Oncol 38(5):479\u2013482","journal-title":"Am J Clin Oncol"},{"issue":"1","key":"9984_CR66","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.clgc.2015.07.019","volume":"14","author":"F Maines","year":"2016","unstructured":"Maines F, Caffo O, De Giorgi U et al (2016) Safety and clinical outcomes of abiraterone acetate after docetaxel in octogenarians with metastatic castration-resistant prostate cancer: results of the Italian compassionate use named patient programme. Clin Genitourin Cancer 14(1):48\u201355","journal-title":"Clin Genitourin Cancer"},{"issue":"5","key":"9984_CR67","doi-asserted-by":"crossref","first-page":"443","DOI":"10.2217\/fon-2017-0385","volume":"14","author":"V Prati","year":"2018","unstructured":"Prati V, Ruatta F, Aversa C, Gernone A, Galizia D, Bonzano A, Torino S, Nuzzolese I, Marandino L, Aglietta M, Ortega C (2018) Cardiovascular safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients: a prospective evaluation. Future Oncol 14(5):443\u2013448","journal-title":"Future Oncol"},{"issue":"8","key":"9984_CR68","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s00345-014-1406-2","volume":"33","author":"AS Merseburger","year":"2015","unstructured":"Merseburger AS, Hammerer P, Rozet F (2015) el al. Androgen deprivation therapy in castrate-resistant prostate cancer: how important is GnRH agonist backbone therapy? World J Urol 33(8):179\u2013185","journal-title":"World J Urol"},{"key":"9984_CR69","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.urology.2016.06.024","volume":"96","author":"G Morgia","year":"2016","unstructured":"Morgia G, Russo GI, Tubaro A et al (2016) Prevalence of cardiovascular disease and osteoporosis during androgen deprivation therapy prescription discordant to EAU guidelines: results from a multicenter, cross-sectional analysis from the CHOsIng Treatment for Prostate canCEr (CHOICE) Study. Urology 96:165\u2013170","journal-title":"Urology"},{"issue":"31","key":"9984_CR70","doi-asserted-by":"crossref","first-page":"3566","DOI":"10.1200\/JCO.2016.70.7794","volume":"35","author":"P Rajan","year":"2017","unstructured":"Rajan P, Sooriakumaran P, Nyberg T, Akre O, Carlsson S, Egevad L, Steineck G, Wiklund NP (2017) Effect of comorbidity on prostate cancer-specific mortality: a prospective observational study. J Clin Oncol 35(31):3566\u20133574","journal-title":"J Clin Oncol"}],"container-title":["Heart Failure Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-020-09984-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10741-020-09984-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-020-09984-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,11]],"date-time":"2022-01-11T18:35:58Z","timestamp":1641926158000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10741-020-09984-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,4]]},"references-count":70,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["9984"],"URL":"https:\/\/doi.org\/10.1007\/s10741-020-09984-2","relation":{},"ISSN":["1382-4147","1573-7322"],"issn-type":[{"value":"1382-4147","type":"print"},{"value":"1573-7322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,4]]},"assertion":[{"value":"4 June 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}